While numerous preclinical studies already suggested the cyclin D–CDK4/6 axis as an attractive target in HER2-positive breast cancer (including cancers resistant to HER2-targeting drugs), clinical studies have mainly focused on ER-positive, HER2-negative breast cancer. This evidence concerns the gene CDK4 and cancer.